Towards Healthcare
Metagenomics Market Size Rises USD 8.39 Billion by 2034

Metagenomics Market Strategic Recommendations with Performance

Projections indicate that, metagenomics industry is projected to rise from USD 2.36 billion in 2024 to USD 8.39 billion by 2034, reflecting a CAGR of 13.55% over the next decade.The metagenomics market is expanding due to the growing incidence of infectious diseases as well as rising advancements in metagenomics. North America led the market due to the presence of well-developed industries.

  • Insight Code: 5771
  • No. of Pages: 150+
  • Format: PDF/PPT/Excel
  • Published: June 2025
  • Report Covered: [Revenue + Volume]
  • Historical Year: 2021-2022
  • Base Year: 2023
  • Estimated Years: 2024-2033

About The Author

Deepa Pandey is a focused and detail-oriented market research professional with growing expertise in the healthcare sector, delivering high-quality insights across therapeutic areas, diagnostics, biotechnology, and healthcare services.

She began her research career at Precedence Research, where she contributed to a wide range of healthcare industry studies, helping build a strong foundation in market intelligence and strategic research. Currently, Deepa plays a critical role at Towards Healthcare, while also extending her research capabilities across Statifacts, supporting cross-industry intelligence initiatives with a focus on healthcare.

Her ability to distill complexity into clarity has made her a trusted contributor to both internal teams and external clients across the healthcare value chain. By combining professionalism with an evolving depth in healthcare research, Deepa consistently adds value to projects that demand critical thinking, market precision, and industry-specific knowledge. Her contributions help organizations navigate the complexities of regulated markets and make data-backed growth decisions.

FAQ's

The global metagenomics market is projected to reach USD 8.39 billion by 2034, up from USD 2.68 billion in 2025, signaling a high-growth opportunity for investors and innovators, especially in areas such as personalized medicine, clinical diagnostics, and environmental monitoring.

North America leads the market with a 41% share in 2024, driven by established biotech infrastructure and R&D investments.

Environmental microbiology leads the application share, but clinical diagnostics is emerging as the fastest-growing segment.

Next-generation sequencing (NGS), especially shotgun and 16S sequencing, are significantly enhancing speed and accuracy.

Notable players include Illumina, Thermo Fisher Scientific, Oxford Nanopore, QIAGEN, and Roche.

The complexity of data interpretation, high cost of sequencing platforms, and the need for skilled bioinformaticians are key barriers.